TNFα Inhibitors in Spondyloarthritis and Rheumatoid Arthritis - Clinical and Laboratory Perspectives

This webinar explores the clinical utility of therapeutic drug monitoring (TDM) for TNFa inhibitors such as adalimumab and infliximab.

Therapeutic drug monitoring (TDM) of TNFa inhibitors is not currently part of the clinical routine, although more than 500,000 patients in the U.S. receive this drug therapy for various diseases. TDM may be useful in preventing adverse events or drug dose adjustment to better treat patients and reduce cost burden.

Key learning objectives

• Explain the clinical utility of TNFa inhibitors in spondyloarthritis and rheumatoid arthritis
• Discuss the importance of drug-level monitoring in patients under TNFa inhibitor therapy

Accreditation statement

SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.^® Program.